Overview

JenaValve Technology, Inc. develops the Trilogy Transcatheter Heart Valve System, which is indicated for the treatment of symptomatic, severe native tricuspid aortic valve regurgitation in high-risk patients.

Therapeutic areas

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to JenaValve Technology, Inc. in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.

For suppliers

Is this JenaValve Technology, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.